KR890013018A - 퀴놀리진 및 퀴놀리지논 유도체의 의약품 제조 용도 - Google Patents

퀴놀리진 및 퀴놀리지논 유도체의 의약품 제조 용도 Download PDF

Info

Publication number
KR890013018A
KR890013018A KR1019890002061A KR890002061A KR890013018A KR 890013018 A KR890013018 A KR 890013018A KR 1019890002061 A KR1019890002061 A KR 1019890002061A KR 890002061 A KR890002061 A KR 890002061A KR 890013018 A KR890013018 A KR 890013018A
Authority
KR
South Korea
Prior art keywords
group
alkyl
compound
hydrogen
halogen
Prior art date
Application number
KR1019890002061A
Other languages
English (en)
Inventor
더블유.기토스 머리스
피.밀러 프랜시스
엠.소렌슨 스티븐
아르.포자드 존
모지 펄
쥐.펄프레이먼 마이클
씨.쳉 흐시엔
Original Assignee
게리 디.스트리트
머렐 다우 파마슈티칼스 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP88400417A external-priority patent/EP0329904A1/en
Priority claimed from EP88400416A external-priority patent/EP0329903A1/en
Priority claimed from EP88400418A external-priority patent/EP0329905A1/en
Priority claimed from EP88400415A external-priority patent/EP0329902A1/en
Application filed by 게리 디.스트리트, 머렐 다우 파마슈티칼스 인크. filed Critical 게리 디.스트리트
Publication of KR890013018A publication Critical patent/KR890013018A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

내용 없음.

Description

퀴놀리진 및 퀴놀리지논 유도체의 의약품 제조 용도
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (10)

  1. 불안증, 정신질환 및 녹내장 치료용 의약품 및 위의 능동성 증진용 의약품 제조에 있어서, 하기 일반식(Ⅰ)의 화합물 및 그의 제약적으로 허용되는 산 부가염 및 4급 암모뉴염의 용도.
    식중, A는 H2,O(H)(OH)(OH)2또는 N-OH기를 나타내고, B는 H2,(H)(CH3),CH2또는 (H)(CH2NR3R4)기를 나타내며, 이때 R3및 R4는 C2-4알킬기를 나타내거나 또는 R3과 R4가 함께 테트라메틸렌, 펜타메틸렌 또는 CH2CH2-O-CH2CH2-기를 나타내고, R1은 하기 구조식들은 나타내며,
    상기 구조식에서, Z는 NR9,O 또는 S를 나타내고, R5, R6및 R8은 각각 수소, 할로겐 C1-3알킬 또는 C1-3알콕시를 나타내며, R7은 수소, 아미노, (C1-4알킬)아미노, (C1-4알킬)2아미노, 알콕시 또는 니트로기를 나타내며, R9는 수소, C1-4알킬 또는 페닐(C1-2알킬)기를 나타내며, R10은 수소, 할로겐, C1-4알킬, C1-4알콕시, 히드록시, 시아노 또는 -CONH2기를 나타내며, R11은 수소, 할로겐 C1-4알킬 또는 페닐기를 나타내며, 파선은 환 상에 위치한 산소 치환체의 배열이 엔도 또는 엑소가 될 수 있음을 나타낸다.
  2. 화합물이 엔도-핵사히드로-8-(3-인돌릴카르보닐옥시)-2,6-메타노-2H-퀴놀리진-3-(4H)-온인 제1항에 의한 의약품.
  3. 제1항에 있어서, 불안증을 치료하기 위한 당해 화합물의 용도.
  4. 제1항에 있어서, 정신질환을 치료하기 위한 당해 화합물의 용도.
  5. 제1항에 있어서, 녹내장을 치료하기 위한 당해 화합물의 용도.
  6. 제1항에 있어서, 위의 능동성을 증진시키기 위한 당해 화합물의 용도.
  7. 하기 일반식(Ⅱ)의 화합물 및 그의 제약적으로 허용되는 산 부가염 및 4급 암모늄염의 용도식중, A는 H2,O(H)(OH)(OH)2또는 N-OH기를 나타내고, B는 H2,(H)(CH3),CH2또는 (H)(CH2NR3R4)기를 나타내며, 이때 R3및 R4는 C2-4알킬기를 나타내거나 또는 R3과 R4가 함께 테트라메틸렌, 펜타메틸렌 또는 CH2CH2-O-CH2CH2-기를 나타내고, R1은 하기 구조식들은 나타내며,
    상기 구조식 중 R9는 수소, C1-4알킬 또는 페닐(C1-2알킬)기를 타나내며, R10은 수소, 할로겐, C1-4알킬, C1-4알콕시, 히드록시, 시아노 또는 -CONH2기를 나타내며, 파선은 환 상에 위치한 산소 치환체의 배열이 엔도 또는 엑소가 될 수 있음을 나타낸다.
  8. 제7항에 있어서, 엔도-헥사히드로-8-(1-메틸-3-인다졸릴카르보닐옥시)-2,6-메타노-2H-퀴놀리진-3(4H)-온인 화합물.
  9. 편두통 및 구토 치료용 의약의 제조에 있어서, 제7항의 화합물의 용도.
  10. 하기 일반식 Ⅲ의 알코올 또는 그의 반응 유도체을 반응 1당량의 일반식(Ⅳ)의 산과 반응시키서, A'이 H2또는 0이고, B'이 H2인 일반식(Ⅱ)'의 화합물을 얻고, 이어서 임의로 a) 케톤 생성물을 붕수소와 알칼리 금속으로 환원시켜서 A'가 (H)(OH)인 화합물을 제조하거나, b) 케톤 생성물을 히드록실아민 염산염과 반응시켜서, A가 N-OH인 화합물을 제조하거나, c) 케톤 생성물을 에틸렌 디티올 또는 트리메틸렌디티올로 처리하여 디티오케톤으로 전환시킨 후, 라네이니켈 존재하에 히드라진으로 환원시켜서, A'가 H2인 화합물을 제조하거나, 또는 d) 케톤 생성물을 포름알데히드 및 적합한 2급 아민과 반응시켜서, B'이 (H)(CH2NR3R4)인 화합물을 제조하고, 이중 B'가 디메틸아미노메틸기인 화합물을 가열하여 B'인 CH2기인 화합물을 제조하고, 더 나아가서 이를 수소 첨가 반응시켜서 B'(H)(CH3)인 화합물을 얻는 것을 특징으로 하는, 하기 일반식(Ⅱ)'의 화합물 및 그들의 제약적으로 허용되는 산 부가염 및 4급 암모늄의 제조방법.
    식중, A는 H2,O(H)(OH)(OH)2또는 N-OH기를 나타내고, B는 H2,(H)(CH3),CH2또는 (H)(CH2NR3R4)기를 나타내며, 이때 R3및 R4는 C2-4알킬기를 나타내거나 또는 R3과 R4가 함께 테트라메틸렌, 펜타메틸렌 또는 CH2CH2-O-CH2CH2-기를 나타내고, R1 '은 하기 구조식들은 나타내며,상기 구조식에서, R0은 수소, C1-4알킬 또는 페닐(C1-2알킬)기를 나타내며, R10은 수소, 할로겐, C1-4알킬, C1-4알콕시, 히드록시, 시아노 또는 -CONH2기를 나타내며, R11은 수소, 할로겐 C1-4알킬 또는 페닐기를 나타내며, 파선은 환 상에 위치한 산소 치환체의 배열이 엔도 또는 엑소가 될 수 있음을 나타냄)
    (식중, A'는 H2또는 0를 나타냄)
    R1COOH (Ⅳ)
    (식중, R1은 상기 정의한 바와 같음).
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019890002061A 1988-02-23 1989-02-22 퀴놀리진 및 퀴놀리지논 유도체의 의약품 제조 용도 KR890013018A (ko)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
EP88400417A EP0329904A1 (en) 1988-02-23 1988-02-23 Use of quinolizine and quinolizinone derivatives in the manufacture of medicaments for the treatment of anxiety
US88400415.1 1988-02-23
EP88400416A EP0329903A1 (en) 1988-02-23 1988-02-23 Use of quinolizinone and quinolizine derivatives in the manufacture of medicaments for the treatment of glaucoma
US88400418.5 1988-02-23
US88400416.9 1988-02-23
EP88400418A EP0329905A1 (en) 1988-02-23 1988-02-23 Use of quinolizine and quinolizinone derivatives in the manufacture of medicaments for increasing gastric motility
EP88400415A EP0329902A1 (en) 1988-02-23 1988-02-23 Use of quinolizinone and quinolizine derivatives in the manufacture of medicaments for the treatment of psychosis
US88400417.7 1988-02-23
US18563188A 1988-04-26 1988-04-26
US185,631 1988-04-26

Publications (1)

Publication Number Publication Date
KR890013018A true KR890013018A (ko) 1989-09-20

Family

ID=27513624

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019890002061A KR890013018A (ko) 1988-02-23 1989-02-22 퀴놀리진 및 퀴놀리지논 유도체의 의약품 제조 용도

Country Status (10)

Country Link
EP (1) EP0329932B1 (ko)
JP (1) JPH02288880A (ko)
KR (1) KR890013018A (ko)
AT (1) ATE129153T1 (ko)
AU (1) AU624115B2 (ko)
DE (1) DE68924545T2 (ko)
DK (1) DK175643B1 (ko)
ES (1) ES2080727T3 (ko)
GR (1) GR3018299T3 (ko)
IE (1) IE72504B1 (ko)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU631632B2 (en) * 1989-04-21 1992-12-03 Novartis Ag Therapeutic use of 5-ht3 receptor antagonists
EP0492020A1 (en) * 1990-12-21 1992-07-01 Merrell Dow Pharmaceuticals Inc. Use of certain esters of hexahydro-8-hydroxy-2,6-methano-2H-quinolizin-3(4H)-one and related compounds for treating cognitive disorders
US5508287A (en) * 1992-02-24 1996-04-16 Merrell Pharmaceuticals Inc. 2,6-methano-2H-quinolizin derivative as 5-HT3 -receptor antagonist
NZ249346A (en) * 1992-02-24 1995-10-26 Merrell Dow Pharma 2,6-methano-2h-quinolizine ester derivatives and medicaments thereof
CA2679870A1 (en) * 2007-03-23 2008-10-02 Abbott Laboratories Azaadamantane ester and carbamate derivatives and methods of use thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2531083B1 (fr) * 1982-06-29 1986-11-28 Sandoz Sa Nouveaux derives de la piperidine, leur preparation et leur utilisation comme medicaments
DE3429830A1 (de) * 1983-08-26 1985-03-07 Sandoz-Patent-GmbH, 7850 Lörrach Automatische carbonsaeure- und sulfonsaeureester oder -amide
FR2557110B1 (fr) * 1983-12-23 1989-11-24 Sandoz Sa Nouveaux derives d'amines cycliques, leur preparation et leur utilisation comme medicaments
DE3680123D1 (en) * 1985-01-23 1991-08-14 Glaxo Group Ltd Tetrahydrocarbazolonderivate.
DE3689974T2 (de) * 1985-03-14 1994-11-03 Beecham Group Plc Arzneimittel zur Behandlung von Emesis.
GB8525913D0 (en) * 1985-10-21 1985-11-27 Beecham Group Plc Compounds
GB8511988D0 (en) * 1985-05-11 1985-06-19 Beecham Group Plc Compounds
GB8520616D0 (en) * 1985-08-16 1985-09-25 Beecham Group Plc Compounds
GB8523211D0 (en) * 1985-09-19 1985-10-23 Beecham Group Plc Compounds
EP0220011A3 (en) * 1985-10-12 1990-01-03 Beecham Group Plc Use of azabicloalkylbenzamides in the treatment of gastrointestinal motility disorders, migraine, emesis, cluster headaches, trigeminal neuralgia and arrhythmia
US4910193A (en) * 1985-12-16 1990-03-20 Sandoz Ltd. Treatment of gastrointestinal disorders
ZA878096B (en) * 1986-11-03 1988-04-26 Merrell Dow Pharmaceuticals Inc. Esters of hexahydro-8-hydroxy-2,6-methano-2h-quinolizin-3(4h)-one and related compounds
EP0330788A1 (en) * 1988-03-01 1989-09-06 Merrell Dow Pharmaceuticals Inc. Use of quinolizine and quinolizinone derivatives in the manufacture of medicaments for the treatment of cardiac arrhythmia

Also Published As

Publication number Publication date
ES2080727T3 (es) 1996-02-16
EP0329932A3 (en) 1992-08-05
EP0329932B1 (en) 1995-10-18
DE68924545T2 (de) 1996-03-21
AU3021489A (en) 1989-08-24
JPH02288880A (ja) 1990-11-28
GR3018299T3 (en) 1996-03-31
IE890564L (en) 1989-08-23
DE68924545D1 (de) 1995-11-23
DK80989A (da) 1989-08-24
AU624115B2 (en) 1992-06-04
ATE129153T1 (de) 1995-11-15
IE72504B1 (en) 1997-04-23
DK175643B1 (da) 2005-01-03
DK80989D0 (da) 1989-02-22
EP0329932A2 (en) 1989-08-30

Similar Documents

Publication Publication Date Title
US3655663A (en) 4-(3-secondary amino-2-hydroxy-proxy) 1 2 5-thiadiazoles
US3740443A (en) Bradycardia compositions
US20060287520A1 (en) Synthesis of salinosporamide A and analogues thereof
KR880001656A (ko) 1,2,3,3a,8,8a-헥사하이드로-3a,8(및 1,3a,8)-디(및 트리)메틸피롤로 [2,3-b] 인돌 및 이의 제조방법
IE50186B1 (en) 3-aminopropoxy derivatives,their preparation and pharmaceutical compositions containing them
US3755413A (en) 1-cyanophenoxy-2-hydroxy-3-(cycloalkyl-amino)-propanes
GB1410511A (en) Thiazole cardiovascular agnets
GB1148717A (en) Phenylbenz (f)-2,5-oxazocine derivatives and homologues and pharmaceutical compositions
KR890013018A (ko) 퀴놀리진 및 퀴놀리지논 유도체의 의약품 제조 용도
KR920006318A (ko) 치환된-4-아미노-3-피리디놀, 이의 제조방법 및 이를 포함하는 약제로서의 이의 용도
US3968214A (en) 5-Methylthio-pyrimidine vasodilators
US6867226B2 (en) Serotonin 5-HT3 receptor partial activator
EP0411912B1 (en) Coumarin derivatives, their preparation and their use in the treatment of cerebrovascular disorders
HUT47531A (en) Process for producing amide derivatives and pharmaceuticals comprising such compounds
CA1336911C (en) Serotonin antagonists
HUT61718A (en) Process for producing phenylethanolamino and phenylethanolamino methyltetraline derivatives
SU1187723A3 (ru) Способ получени гидрохлорида 2-оксиметил- 6 -метил- 4- @ - толилтиено/2,3 - @ / пиперидина
US3256278A (en) N-hydroxy ethyl-ortho acetyl and carbalkoxy amino phenyl-glyoxamides and process formaking 2-orthoamino phenyl-morpholines
WEATHERBEE et al. A New Approach to Tertiary β-Chloroalkylamines. Synthesis of β-Chloroalkylaminomethylhydroquinones1
US3833655A (en) Amino-dibenzo(a,d)cyclohepta(1,4)dien-5-one compounds
US3337546A (en) Certain 1, 3 oxazines and a process for their preparation
HU196069B (en) Process for production of 8-/dihydropiridil-carbamoiloxi-methil/-ergolines and medical compounds containing these compositions
US3953493A (en) Substituted sulfonamide derivatives as anthelmintic agents
US4868315A (en) Novel aryloxycycloalkanolaminoalkylene aryl ketones
KR860007255A (ko) 벤조[c]-1,5-나프티리딘의 제조방법

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application